Important Information for Your Patients Considering SLIT-Tablet Therapy for HDM-Induced Allergic Rhinitis

“If a patient was diagnosed with eosinophilic esophagitis or has unstable asthma, then ODACTRA is not recommended,” says Dr. Bardelas. “Other contraindications include severe heart disease and uncontrolled blood pressure. Treatment with beta blockers is a relative contraindication for ODACTRA, because epinephrine injection may not work as well in patients who take them. In patients who have mouth sores due to dental work, treatment with SLIT-tablets should be postponed until healing occurs.” 

Patient acceptance of SLIT-tablet therapy

There is an underserved patient population with HDM-induced AR that may be appropriate to initiate allergen immunotherapy (AIT). Even with a provider-recommended AIT discussion, approximately 3 in 4 patients do not initiate SCIT, and of those adults who initiate SCIT, a significant number (69.8%) discontinue within 3 years13. By having SLIT-tablets as an additional option, allergy specialists can reach out to more patients who are in need of AIT.

Dr. Bardelas notes that there was a high rate of acceptance of SLIT-tablet therapy among patients with HDM-induced AR in clinical studies.

 “The acceptance rate of SLIT-tablets among patients is at least 90%,” says Dr. Bardelas. “So, this treatment is very well received by the patients and represents a suitable alternative for those patients who cannot take allergy injections or do not have the time for regular office visits.”

ODACTRAImportant Safety Information


  • ODACTRA can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal restriction.
  • Do not administer ODACTRA to patients with severe, unstable or uncontrolled asthma.
  • Observe patients in the office for at least 30 minutes following the initial dose.
  • Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.
  • ODACTRA may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.
  • ODACTRA may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

ODACTRA is contraindicated in patients with:

  • Severe, unstable, or uncontrolled asthma
  • A history of any severe systemic allergic reaction
  • A history of any severe local reaction after taking any sublingual allergen immunotherapy
  • A history of eosinophilic esophagitis
  • Hypersensitivity to any of the inactive ingredients [gelatin, mannitol and sodium hydroxide] contained in this product

ODACTRA can cause systemic allergic reactions including anaphylaxis which may be life-threatening. In addition, ODACTRA can cause severe local reactions, including laryngopharyngeal swelling, which can compromise breathing and be life-threatening. Educate patients to recognize the signs and symptoms of these allergic reactions and instruct them to seek immediate medical care and discontinue therapy should any of these occur. Allergic reactions may require treatment with epinephrine.

Prescribe auto-injectable epinephrine to patients receiving ODACTRA. Instruct patients to recognize the signs and symptoms of a severe allergic reaction and in the proper use of emergency auto-injectable epinephrine. Instruct patients to seek immediate medical care upon use of auto-injectable epinephrine and to stop treatment with ODACTRA. Review the epinephrine package insert for complete information.

Administer the initial dose of ODACTRA in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases and prepared to manage a life-threatening systemic or local allergic reaction. Observe patients in the office for at least 30 minutes following the initial dose of ODACTRA.